Can Next Generation Psychedelics Treat Mental Illness? | Mindset Pharma | DMT, 5-MEO-DMT
In today’s episode of the Psychedelic Spotlight Podcast, The Psychedelic Investor sits down with James Lanthier, CEO of Mindset Pharma (CSE: MSET, OTC: MSSTF).
Mindset Pharma is a psychedelic medicines company working on creating next-generation psychedelics to be used both in a therapy and microdosing setting.
Mindset has three variations of psilocybin, the active ingredient in Magic Mushrooms. Two of these are being used in therapy settings, and one will be used for microdosing. Finally, the company has one family of compounds inspired by DMT and 5-MEO-DMT.
Excitingly, Mindset is moving towards beginning clinical trials in 2022.
On the day that the interview was recorded, Mindset released some major news; they are teaming up with Otsuka Pharmaceuticals to bring two of their drug families to market. As part of this deal, Mindset will receive $5 million USD upfront, and then Otsuka will also pay for some development costs.
In the long term, this deal has great potential for Otsuka.
To learn more about Mindset pharma and its stock, listen to the full interview. In it we attempt to answer questions such as:
Can psychedelics treat mental illnesses such as depression?
Are next-generation psychedelics better than the originals?
What is happening in the brain when a person takes psychedelics?
Enjoy the episode!
You can find Mindset Pharma trading on the Canadian Securities Exchange under the symbol $MSET and on the American OTC market under the symbol $MSSTF.
*To learn more about Mindset Pharma visit their website: https://www.mindsetpharma.com/
#MindsetPharma #DMT #microdosing